clinical trial · NCT05068752
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute·phase2·completed·n = 10
Pancreas CancerVemurafenibSorafenib
brief summary
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
started
Oct 28, 2021
primary completion
Nov 8, 2024
completion
Dec 13, 2024
last updated
Mar 30, 2026
official title
A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol